Detalles de la búsqueda
1.
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Gastroenterology
; 160(7): 2354-2366.e11, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667488
2.
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Acta Oncol
; 57(1): 67-73, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202611
3.
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Int J Colorectal Dis
; 33(7): 927-936, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748708
4.
A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
Acta Oncol
; 56(9): 1161-1167, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28488912
5.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
BMC Cancer
; 15: 239, 2015 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25885472
6.
Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark.
Int J Cancer
; 133(9): 2201-6, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23616071
7.
Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
Acta Oncol
; 52(1): 82-90, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23205744
8.
Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Acta Oncol
; 51(6): 781-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22462654
9.
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Breast Cancer Res Treat
; 127(2): 345-55, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20556506
10.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
BMC Cancer
; 9: 185, 2009 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19531212
11.
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Acta Oncol
; 48(4): 522-31, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19173092
12.
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Lancet Oncol
; 9(1): 23-8, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18083065
13.
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications.
Acta Oncol
; 47(4): 789-94, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18465350
14.
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
J Clin Pathol
; 60(4): 397-404, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16775123
15.
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
J Clin Oncol
; 23(30): 7483-90, 2005 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16234514
16.
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors.
Pharmacogenetics
; 12(6): 473-8, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12172216
17.
Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.
APMIS
; 122(9): 750-4, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24372587
18.
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Eur J Cancer
; 49(14): 2986-94, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23756360
19.
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Breast
; 21(5): 662-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22854050
20.
High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit.
Am J Clin Pathol
; 136(1): 145-51, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21685042